Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347545 | 0.86 | AVPR1A (0.39) | AVPR1AKCNH2GABRA5 | |
| SCHEMBL1346833 | 0.86 | TACR3 (0.41) | AVPR1AROCK1 | |
| SCHEMBL3399967 | 0.84 | AVPR1A (0.37) | AVPR1A | |
| SCHEMBL1347807 | 0.79 | AVPR1A (0.39) | AVPR1AKCNH2SRD5A1GABRG2GABRB3 | |
| SCHEMBL315206 | 0.74 | BRD4 (0.45) | AVPR1AKCNH2GABRG2GABRB3GABRA5 | |
| SCHEMBL16774919 | 0.74 | AVPR1A (0.53) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL315096 | 0.70 | TNKS2 (0.34) | KCNH2 | |
| SCHEMBL314713 | 0.70 | TNKS2 (0.40) | AVPR1AKCNH2AVPR2OXTRGABRG2 | |
| SCHEMBL314133 | 0.70 | TNKS2 (0.40) | AVPR1AKCNH2AVPR2OXTRGABRG2 | |
| SCHEMBL314365 | 0.70 | TNKS2 (0.40) | AVPR1AKCNH2AVPR2OXTRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | claimed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | claimed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | claimed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | TGFBR1, TGFBR2, ACVR1 | AVPR1A 3040/4885KCNH2 2799/4885SRD5A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.